Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the third international workshop

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 2, 2009, Pages 340-350

  Eastell, Richard ^a,n   Arnold, A ^b   Brandi, M L ^c   Brown, E M ^o   D'Amour, P ^d,e   Hanley, D A ^f   Sudhaker Rao, D ^g   Rubin, M R ^o   Goltzman, D ⁱ   Silverberg, S J ^h   Marx, S J ^o   Peacock, M ^j   Mosekilde, L ^k   Bouillon, R ^l   Lewiecki, E M ^m  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF MONTREAL   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g HENRY FORD HOSPITAL   (United States)

^h Columbia University College of Physicians and Surgeons ^*  (United States)

ⁱ MCGILL UNIVERSITY   (Canada)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k AARHUS UNIVERSITY HOSPITAL   (Denmark)

^l UNIVERSITY OF LEUVEN   (Belgium)

^m UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

ⁿ NORTHERN GENERAL HOSPITAL   (United Kingdom)

^o NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM SENSING RECEPTOR; FUROSEMIDE; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

ABDOMINAL RADIOGRAPHY; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONSENSUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ECHOGRAPHY; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GLOMERULUS FILTRATION RATE; HETEROZYGOTE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; JAW TUMOR; KIDNEY FUNCTION; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 GENE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A GENE; NEPHROLITHIASIS; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

EID: 59749089672     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1758     Document Type: Conference Paper

References (85)

1. Gao P, D'Amour P 2005 Evolution of the parathyroid hormone (PTH) assay - importance of circulating PTH immunoheterogeneity and of its regulation. Clin Lab 51:21-29
2. Brossard JH, Whittom S, Lepage R, D'Amour P 1993 Carboxyl-terminal fragments of parathyroid hormone are not secreted preferentially in primary hyperparathyroidism as they are in other hypercalcemic conditions. J Clin Endocrinol Metab 77:413-419
3. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang CA, Potts Jr JT, Segre GV 1987 Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364-1367
4. National Kidney Foundation 2003 K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1-S200
5. Cantor T 2005 Parathyroid hormone assay drift: an unappreciated problem in dialysis patient management. Sem Dialysis 18:359-364
6. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, Massart C, Monge M, Myara J, Parent X, Plouvier E, Houillier P 2006 Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 70:345-350
7. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D'Amour P 1998 A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44:805-809
8. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A 2000 A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753-761
9. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D'Amour P 2001 Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 142:1386-1392
10. 2D synthesis. Kidney Int 72:1330-1335
11. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H 1999 A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 84:4287-4290
12. D'Amour P, Brossard JH, Rousseau L, Roy L, Gao P, Cantor T 2003 Aminoterminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 49:2037-2044
13. Rubin MR, Silverberg SJ, D'Amour P, Brossard JH, Rousseau L, Sliney Jr J, Cantor T, Bilezikian JP 2007 An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1-84) is overproduced in parathyroid carcinoma. Clin Chem 53:1470-1476
14. Aloia JF, Feuerman M, Yeh JK 2006 Reference range for serum parathyroid hormone. Endocr Pract 12:137-144
15. Freaney R, McBrinn Y, McKenna MJ 1993 Secondary hyperparathyroidism in elderly people: combined effect of renal insufficiency and vitamin D deficiency. Am J Clin Nutr 58:187-191
16. Liu M, Gordon JM, Labranche JM, Murray TM, Vieth R, Shear NH 1997 Seasonal prevalence of vitamin D deficiency in institutionalized older adults. J Am Geriatr Soc 45:598-603
17. Lips P 2001 Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 22:477-501
18. Vieth R, Ladak Y, Walfish PG 2003 Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J Clin Endocrinol Metab 88:185-191
19. Maggio D, Cherubini A, Lauretani F, Russo RC, Bartali B, Pierandrei M, Ruggiero C, Macchiarulo MC, Giorgino R, Minisola S, Ferrucci L 2005 25(OH)D serum levels decline with age earlier in women than in men and less efficiently prevent compensatory hyperparathyroidism in older adults. J Gerontol 60A:1414-1419
20. Harris SS, Soteriades E, Coolidge JA, Mudgal S, Dawson-Hughes B 2000 Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J Clin Endocrinol Metab 85:4125-4130
21. Kinyamu HK, Gallagher JC, Rafferty KA, Balhorn KE 1997 Dietary calcium and vitamin D intake in elderly women: effect on serum parathyroid hormone and vitamin D metabolites. Am J Clin Nutr 67:342-348
22. Bates CJ, Carter GD, Mishra GD, O'Shea A, Jones J, Prentice A 2003 In a population study, can parathyroid hormone aid the definition of adequate vitamin D status? A study of people aged 65 years and over from the British National Diet and Nutrition Survey. Osteoporos Int 14:152-159
23. Steingrimsdottir L, Gunnarsson O, Indridason OS, Franzson L, Sigurdsson G 2005 Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA 294:2336-2341
24. Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S 1985 Evidence for alteration of the vitamin D-endocrine system in obese subjects. J Clin Invest 76:370-373
25. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF 2000 Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 72:690-693
26. Lips P, Wiersinga A, van Ginkel FC, Jongen MJ, Netelenbos JC, Hackeng WH, Delmas PD, van der Vijgh WJ 1988 The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab 67:644-650
27. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS 1998 Hypovitaminosis D in medical inpatients. N Engl J Med 1998 338:777-783
28. Malabanan A, Veronikis IE, Holick MF 1998 Redefining vitamin D insufficiency. Lancet 351:805-806
29. Peacock M 1998 Effects of calcium and vitamin D insufficiency on the skeleton. Osteoporos Int 8 (Suppl):S45-S51
30. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ 1997 Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7:439-443
31. Dawson-Hughes B, Harris SS, Dallal GE 1997 Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr 65:67-71
32. Carter GD, Carter R, Jones J, Berry J 2004 How accurate are assays for 25-hydroxyvitamin D? Data from the International Vitamin D External Quality Assessment Scheme. Clin Chem 50:2195-2197
33. Heaney RP, Dowell MS, Hale CA, Bendich A 2003 Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 22:142-146
34. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B 2004 Positive association between 25-hydroxyvitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 116:634-639
35. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B 2006 Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84:18-28
36. 3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 13:257-264
37. Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, Baulieu EE 2001 Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 86:3086-3090
38. 3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327:1637-1642
39. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE 1997 Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670-676
40. D'Amour P, Brossard JH, Rousseau L, Nguyen-Yamamoto L, Nassif E, Lazure C, Gauthier D, Lavigne JR, Zahradnik RJ 2005 Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 68:997-1007
41. Gao P, Scheibel S, D'Amour P, John MR, Rao DS, Schmidt-Gayk H, Cantor TL 2001 Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone (1-84): implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605-614
42. D'Amour P, Brossard JH, Räkel A, Rousseau L, Albert C, Cantor T 2005 Evidence that the amino-terminal composition of non-(1-84) parathyroid hormone fragments starts before position 19. Clin Chem 51:169-176
43. Boudou P, Ibrahim F, Cormier C, Sarfatti E, Souberbielle JC 2006 Unexpected serum parathyroid hormone profiles in some patients with primary hyperparathyroidism. Clin Chem 51:757-760
44. Silverberg SJ, Gao P, Brown I, Logerfo P, Cantor TL, Bilezikian JP 2003 Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab 88:4725-4730
45. Carnevale V, Dionisi S, Nofroni I, Romagnoli E, Paglia F, De Geronimo S, Pepe J, Clemente G, Tonnarini G, Minisola S 2004 Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem 50:626-631
46. Boudou P, Ibrahim F, Cormier C, Chabas A, Sarfati E, Souberbielle JC 2005 Third- or second-generation parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism. J Clin Endocrinol Metab 90:6370-6372
47. Souberbielle JC, Boudou P, Cormier C 2008 Lessons from second- and third-generation parathyroid hormone assays in primary hyperparathyroidism. J Endocrinol Invest 31:463-469
48. El-Hajj Fuleihan G, Brown EM, Heath III H 2000 Familial benign hypocalciuric hypercalcemia and neonatal primary hyperparathyroidism. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. 2nd ed. San Diego: Academic Press; 1031-1045
49. Marx SJ, Simonds WF, Agarwal SK, Burns AL, Weinstein LS, Cochran C, Skarulis MC, Spiegel AM, Libutti SK, Alexander Jr HR, Chen CC, Chang R, Chandrasekharappa SC, Collins FS 2002 Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res 17(Suppl 2):N37-N43
50. Brown EM 2007 Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 3:122-133
51. Carling T, Szabo E, Bai M, Ridefelt P, Westin G, Gustavsson P, Trivedi S, Hellman P, Brown EM, Dahl N, Rastad J 2000 Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. J Clin Endocrinol Metab 85:2042-2047
52. Simonds WF, James-Newton LA, Agarwal SK, Yang B, Skarulis MC, Hendy GN, Marx SJ 2002 Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 81:1-26
53. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells Jr SA, Marx SJ 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671
54. Marx SJ 2005 Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 5:367-375
55. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J, Atkinson MJ 2006 Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA [Erratum (2006) 103:19213] 103:15558-15563
56. Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Vierimaa O, Mäkinen MJ, Tuppurainen K, Paschke R, Gimm O, Koch CA, Gündogdu S, Lucassen A, Tischkowitz M, Izatt L, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P, Aaltonen LA 2007 Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 92:3321-3325
57. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Hoog A, Heath 3rd H, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo LO, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, Teh BT, Larsson C, Hobbs MR 2002 HRPT2, encoding parafibromin, is mutated in HPT-jaw tumor syndrome. Nat Genet 32:676-680
58. Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A 2003 Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349:1722-1729
59. Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ 2004 Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 89:96-102
60. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP 1999 A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249-1255
61. Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, Talpos GB, Parfitt AM 2000 Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 85:1054-1058
62. Rao DS, Agarwal G, Talpos GB, Phillips ER, Bandeira F, Mishra SK, Mithal A 2002 Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 17(Suppl 2):N75-N80
63. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L 2005 Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 63:506-513
64. Beyer TD, Chen E, Nilubol N, Prinz RA, Solorzano CC 2007 Short-term outcomes of parathyroidectomy in patients with or without 25-hydroxyvitamin D insufficiency. J Surg Res 143:145-150
65. Silverberg SJ, Shane S, Dempster DW, Bilezikian JP 1999 The effects of vitamin Dinsufficiency in patients with primary hyperparathyroidism. Am J Med 107:561-567
66. Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, Petruschke RA, Chen E, de Papp AE 2005 Prevalence of vitamin D inadequacy among post-menopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90:3215-3224
67. Guardia G, Parikh N, Eskridge T, Phillips E, Divine G, Rao DS 2008 Prevalence of vitamin D depletion among subjects seeking advice on osteoporosis: a five-year cross-sectional study with public health implications. Osteoporos Int 19:13-19
68. Clements MR, Davies M, Fraser DR, Lumb GA, Mawer EB, Adams PH 1987 Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci (Lond) 73:659-664
69. Woodhouse NJ, Doyle FH, Joplin GF 1971 Vitamin-D deficiency and primary hyperparathyroidism. Lancet 2:283-286
70. Lumb GA, Stanbury SW 1974 Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am J Med 56:833-839
71. Rao DS, Phillips ER, Divine GW, Talpos GB 2004 Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89:5415-5422
72. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR 2005 Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 90:2122-2126
73. Binkley N, Krueger D, Gemar D, Drezner MK 2008 Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab 93:1804-1808
74. Carter GD, Carter R, Jones J, Berry J 2004 How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem 50:2195-2197
75. Hathcock JN, Shao A, Vieth R, Heaney R 2007 Risk assessment for Vitamin D. Am J Clin Nut 285:6-18
76. Rao PN 2004 Imaging for kidney stones. World J Urol 22:323-327
77. Bilezikian JP, Potts Jr JT, Fuleihan G, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells Jr SA 2002 Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 17(Suppl 2):N2-N11
78. Sinclair D, Wilson S, Toi A, Greenspan L 1989 The evaluation of suspected renal colic: ultrasound scan versus excretory urography. Ann Emerg Med 18:556-559
79. Vrtiska TJ, Hattery RR, King BF, Charboneau JW, Smith LH, Williamson Jr B, Brakke DM 1992 Role of ultrasound in medical management of patients with renal stone disease. Urol Radiol 14:131-138
80. Sheafor DH, Hertzberg B, Freed KS, Carroll BA, Keogan MT, Delong DM, Nelson RC 2000 Nonenhanced helical CT and US in the emergency evaluation of patients with renal colic: prospective comparison. Radiology 217:792-797
81. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D 1999 A more accurate method to estimate glomerular filtration rate from serum creatinine: anewprediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470
82. Cockcroft DW, Gault MH 1976 Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
83. Gault MH, Longerich LL, Harnett JD, Wesolowski C 1992 Predicting glomerular function from adjusted serum creatinine. Nephron 62:249-256
84. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, Salive M, Jones CP, Agodoa LY 1998 Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 32:992-999
85. Souberbielle JC, Friedlander G, Cormier C 2006 Practical considerations in PTH testing. Clin Chim Acta 366:81-89